Posted on 3/19/20
Teva Pharmaceuticals Near 20-Year Lows
SummaryRecent pullback to $8 presents incredible buying opportunity for long-term share appreciation.Streamlined company with major restructuring ongoing.Balance sheet is improving as net debt to EBITDA improves.Generics . . .
Posted on 3/9/20
Pfizer At Attractive Valuation
SummaryYOY Pfizer is down on revenues and cash flow, stock price reflecting such.Guidance lowered for 2020, but operations becoming streamlined.Coronavirus fears affecting overall market and will . . .
Philadelphia
